Click Therapeutics and Indivior will develop a digital solution for treating substance use disorders, starting with opioid use disorders. Click already signed partnership deals with Otsuka and Verily and Boehringer Mannheim to co-develop digital therapeutics for patients with schizophrenia and major depressive disorder.

The Danish firm’s respiratory syncytial vaccine disappointed in a Phase III trial, marking an unexpected setback after a year of mpox-related successes, prompting all eyes to turn towards a recently-acquired chikungunya vaccine program.

Fourteen new products could be approved in the EU soon, after the European Medicines Agency gave them the thumbs up.

A bumper crop of products are up for an opinion this week by the European Medicines Agency’s human medicines committee, the CHMP, as to whether they should be approved in the EU.